Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 2 of 539 for:    PARTNER II


This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Edwards Lifesciences Identifier:
First received: February 1, 2016
Last updated: October 4, 2016
Last verified: September 2016
The purpose of this trial is to determine the safety and effectiveness of the Edwards Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis.

Condition Intervention Phase
Aortic Stenosis
Device: TAVR with SAPIEN S3 valve
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves: Continued Access Program for SAPIEN 3 Intermediate Risk (S3iCAP)

Resource links provided by NLM:

Further study details as provided by Edwards Lifesciences:

Primary Outcome Measures:
  • Stroke [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Aortic valve reintervention [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Death [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Annular dissection [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Aortic dissection [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Major access site vascular complications [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Unplanned vascular surgery or intervention [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Retroperitoneal bleed [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • GI bleed [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • GU bleed [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Bleeding at access sites [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Enrollment: 1822
Study Start Date: January 2015
Estimated Study Completion Date: August 2021
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SAPIEN 3
Intermediate risk patients receiving SAPIEN S3 valve with Commander or Certitude delivery system
Device: TAVR with SAPIEN S3 valve
Transcatheter aortic valve replacement
Other Names:
  • TAVR
  • TAVI
  • Transcatheter aortic valve replacement

Detailed Description:
This multi-center, single arm registry will provide continued access of the Edwards SAPIEN 3 Transcatheter Heart Valve and delivery systems to severe aortic stenosis patients at intermediate risk for standard aortic valve replacement. Patient data will be entered into the TVT Registry (TVTR) from screening through 1 year including the collection of 5 year follow-up through CMS.

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must be covered by Medicare. This will enable Edwards to link to the CMS database for long term follow-up through 5 years. No other insurance provider will be accepted.
  2. Assessment of intermediate surgical risk defined as STS 4-8% or heart team assessment of intermediate risk factors.
  3. Patient has senile degenerative aortic valve stenosis with echocardiographically derived criteria: mean gradient > 40 mmHg or jet velocity greater than 4.0 m/s and an initial aortic valve area (AVA) of < 0.8 cm2 or indexed EOA < 0.5 cm2/m2. Qualifying echo must be within 60 days of the date of the procedure.
  4. Aortic valve annulus area range (273mm2-680 mm2) per 3D imaging (echo, CT, or MRI).
  5. Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class II or greater.
  6. The heart team agrees (and verified in the case review process) that valve implantation will likely benefit the patient.
  7. Heart team agrees (a priori) on treatment strategy for concomitant coronary disease (if present).
  8. The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
  9. The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which will be conducted as a phone follow-up.

Exclusion Criteria:

  1. Heart team assessment of inoperability (including examining cardiac surgeon).
  2. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment [(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].
  3. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.
  4. Mixed aortic valve disease (aortic stenosis and aortic re-regurgitation with predominant aortic regurgitation >3+).
  5. Pre-existing mechanical or bioprosthetic valve in any position.
  6. Complex coronary artery disease:

    1. Unprotected left main coronary artery
    2. Syntax score > 32 (in the absence of prior revascularization)
  7. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker or ICD is not considered exclusion criteria.
  8. Any patient with a balloon valvuloplasty (BAV) < 30 days of the procedure (unless BAV is a bridge to procedure after a qualifying ECHO).
  9. Patients with planned concomitant surgical or transcatheter ablation for atrial fibrillation.
  10. Leukopenia (WBC < 3000 cell/mL), acute anemia (Hgb < 9 g/dL), thrombocytopenia (Plt < 50,000 cell/mL).
  11. Hypertrophic cardiomyopathy with or without obstruction (HOCM).
  12. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation.
  13. Need for emergency surgery for any reason.
  14. Severe ventricular dysfunction with LVEF < 20%.
  15. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
  16. Active upper GI bleeding within 3 months (90 days) prior to procedure.
  17. A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.
  18. Native aortic annulus size < 16 mm or > 28mm as measured by echocardiogram.
  19. Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 6 months (180 days) of the procedure.
  20. Renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy at the time of screening.
  21. Estimated life expectancy < 24 months (730 days) due to carcinomas, chronic liver disease, chronic renal dis-ease or chronic end stage pulmonary disease.
  22. Expectation that patient will not improve despite treatment of aortic stenosis.
  23. Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta. (Transfemoral)
  24. Iliofemoral vessel characteristics that would preclude safe placement of 14F or 16F introducer sheath such as severe obstructive calcification, severe tortuosity or min-imum average vessel size less than 5.5 mm. (Transfem-oral).
  25. Currently participating in an investigational drug or an-other device study. Note: Trials requiring extended fol-low-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
  26. Active bacterial endocarditis within 6 months (180 days) of procedure.
  27. Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis.
  28. Inability to tolerate anticoagulation/antiplatelet therapy.
  29. For transfemoral approach only: Femoro-iliac vessels < 5.5 mm for the 23 mm and the 26 mm system and < 6.0 mm for the 29 mm system.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02687035

  Show 56 Study Locations
Sponsors and Collaborators
Edwards Lifesciences
Principal Investigator: Susheel Kodali, MD University of Columbia
Principal Investigator: Vinod Thourani, MD Emory University
  More Information

Responsible Party: Edwards Lifesciences Identifier: NCT02687035     History of Changes
Other Study ID Numbers: 2010-12 - S3iCAP 
Study First Received: February 1, 2016
Last Updated: October 4, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Edwards Lifesciences:
Aortic stenosis
Transcatheter Heart Valve

Additional relevant MeSH terms:
Constriction, Pathologic
Aortic Valve Stenosis
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction processed this record on October 25, 2016